Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targacept, AstraZeneca Face Another Failure With NNR Class

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.

You may also be interested in...



Failure Narrows Odds On Targacept Depression Drug; Hope Rests In Remaining Three Trials

Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.

MDD Market Snapshot: Depressing Future For Antidepressants

Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.

AstraZeneca Drops Targacept's Failed ADHD Drug

After receiving disappointing news about one of its Phase 2 NNR drugs, Targacept waits to hear from its partner, AZ

Topics

Related Companies

UsernamePublicRestriction

Register

PS005073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel